Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 7/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.34 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.34 |
| ▸ | GJB2 | P29033 | 1/20 | 0.32 |
| ▸ | FGF1 | P05230 | 2/20 | 0.31 |
| ▸ | FGF2 | P09038 | 2/20 | 0.31 |
| ▸ | VEGFA | P15692 | 2/20 | 0.31 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1096195 | 0.90 | BCHE (0.39) | BCHEVEGFAPTPN1GSTP1 | |
| SCHEMBL1096197 | 0.90 | BCHE (0.39) | BCHEVEGFAPTPN1GSTP1 | |
| SCHEMBL1097346 | 0.90 | BCHE (0.39) | BCHEVEGFAPTPN1GSTP1 | |
| SCHEMBL135298 | 0.89 | APLNR (0.34) | CA1CA2 | |
| SCHEMBL1097290 | 0.88 | BCHE (0.36) | BCHESSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL23818770 | 0.85 | SSTR1 (0.41) | BCHESSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL136626 | 0.84 | APLNR (0.37) | BCHECA1CA2CA9 | |
| SCHEMBL1098026 | 0.83 | ALDH1A1 (0.36) | BCHEGSTP1 | |
| SCHEMBL1098024 | 0.83 | ALDH1A1 (0.36) | BCHEGSTP1 | |
| SCHEMBL14511226 | 0.83 | ALDH1A1 (0.36) | BCHEGSTP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015469-B2 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2015-11-18 | — | — | EP | disclosed |
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8080644-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-12-20 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2253639-A1 | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2010-11-24 | — | — | EP | disclosed |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-11-04 | — | — | US | disclosed |
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | EXIQON A/S (DK) | 2010-10-21 | — | — | US | disclosed |
| US-7572582-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2009-08-11 | — | — | US | disclosed |
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | QIAGEN GMBH (DE) | 2005-12-29 | — | — | US | disclosed |
| EP-1557424-A1 | Bi-cyclic nucleoside, nucleotide and oligonucleoide analogues | Exiqon A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| EP-1015469-B1 | BI- AND TRI-CYCLIC NUCLEOSIDE, NUCLEOTIDE AND OLIGONUCLEOIDE ANALOGUES | EXIQON AS (DK) | 2005-04-13 | — | — | EP | disclosed |
| US-6794499-B2 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES | EXIQON A/S (DK) | 2004-09-21 | — | — | US | disclosed |
| US-6670461-B1 | Bi-, tri, or polycyclic nucleoside analogues having a \"locked\" structure capable of forming heat resistant nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. | EXIQON A/S (DK) | 2003-12-30 | — | — | US | disclosed |
| US-20030144231-A1 | Oligonucleotide analogues | EXIQON A/S (DK) | 2003-07-31 | — | — | US | disclosed |
| US-20030134808-A1 | Oligonucleotide analogues | WENGEL JESPER (DK) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134808-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | BCHE 3572/4885SSTR1 2290/4885SSTR2 2871/4885 |
| US-20030144231-A1 | Oligonucleotide analogues | TARBP1, DCLRE1B, ADAR | BCHE 3572/4885SSTR1 2290/4885SSTR2 2871/4885 |
| US-20100267018-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | BCHE 3843/4885SSTR1 1846/4885SSTR2 2280/4885 |
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | BCHE 3843/4885SSTR1 1846/4885SSTR2 2280/4885 |
| US-20050287566-A1 | BICYCLIC LOCKED NUCLEOSIDE ANALOGUES; using an oligomer to isolate, purify, amplify, detect, identify, quantify or capture a natural or synthetic nucleic acid | POLRMT, POLM, POLN | BCHE 3364/4885SSTR1 2203/4885SSTR2 2927/4885 |
| US-20100279895-A1 | OLIGONUCLEOTIDE ANALOGUES | POLRMT, POLM, POLN | BCHE 3843/4885SSTR1 1846/4885SSTR2 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.